- Home
- ZI vs VRNA Comparison
ZI vs VRNA Comparison
Compare ZI & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZI
- VRNA
- Stock Information
- Founded
- ZI 2007
- VRNA 2005
- Country
- ZI United States
- VRNA United Kingdom
- Employees
- ZI N/A
- VRNA N/A
- Industry
- ZI Computer Software: Prepackaged Software
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- ZI Technology
- VRNA Health Care
- Exchange
- ZI Nasdaq
- VRNA Nasdaq
- Market Cap
- ZI 3.5B
- VRNA 3.4B
- IPO Year
- ZI 2020
- VRNA 2017
- Fundamental
- Price
- ZI $9.95
- VRNA $54.09
- Analyst Decision
- ZI Hold
- VRNA Strong Buy
- Analyst Count
- ZI 22
- VRNA 7
- Target Price
- ZI $13.17
- VRNA $53.14
- AVG Volume (30 Days)
- ZI 7.8M
- VRNA 1.4M
- Earning Date
- ZI 02-25-2025
- VRNA 02-27-2025
- Dividend Yield
- ZI N/A
- VRNA N/A
- EPS Growth
- ZI N/A
- VRNA N/A
- EPS
- ZI 0.02
- VRNA N/A
- Revenue
- ZI $1,221,600,000.00
- VRNA $5,624,000.00
- Revenue This Year
- ZI N/A
- VRNA N/A
- Revenue Next Year
- ZI N/A
- VRNA $568.20
- P/E Ratio
- ZI $414.20
- VRNA N/A
- Revenue Growth
- ZI N/A
- VRNA 1127.95
- 52 Week Low
- ZI $7.65
- VRNA $11.39
- 52 Week High
- ZI $18.70
- VRNA $55.42
- Technical
- Relative Strength Index (RSI)
- ZI 43.04
- VRNA 66.32
- Support Level
- ZI $9.88
- VRNA $43.44
- Resistance Level
- ZI $10.39
- VRNA $55.42
- Average True Range (ATR)
- ZI 0.37
- VRNA 3.43
- MACD
- ZI -0.01
- VRNA 0.48
- Stochastic Oscillator
- ZI 37.94
- VRNA 82.87
About ZI ZoomInfo Technologies Inc
ZoomInfo Technologies Inc provides a go-to-market intelligence platform for sales and marketing teams. Its cloud-based go-to-market data and insights platform deliver comprehensive and high-quality intelligence and analytics to provide sales and marketing professionals with accurate information and insights on the organizations and professionals. Nearly all of its revenue is derived from the United States.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.